Online inquiry

IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ10562MR)

This product GTTS-WQ10562MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets IL23A gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_016584.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 51561
UniProt ID Q9NPF7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL23A, LY­3074828(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) (GTTS-WQ10562MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ8504MR IVTScrip™ mRNA-Anti-ITGAL, hu1124(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA hu1124
GTTS-WQ6210MR IVTScrip™ mRNA-Anti-RABVgp4, CR4098(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CR4098
GTTS-WQ433MR IVTScrip™ mRNA-Anti-AMHR2, 3C23K(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA 3C23K
GTTS-WQ4614MR IVTScrip™ mRNA-Anti-KIR2DL1&KIR2DL2&KIR2DL3&KIR2DS1&KIR2DS2, BMS-986015(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986015
GTTS-WQ14818MR IVTScrip™ mRNA-Anti-CD70, SGN-70(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA SGN-70
GTTS-WQ14321MR IVTScrip™ mRNA-Anti-EGFL7, RG7414(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA RG7414
GTTS-WQ8568MR IVTScrip™ mRNA-Anti-CD47, Hu5F9-G4(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA Hu5F9-G4
GTTS-WQ5353MR IVTScrip™ mRNA-Anti-CD38, CD38-Attenukine(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA CD38-Attenukine
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW